Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMAIN
DRKS00000582Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg - vertreten durch: Leitenden Ärztlichen Direktor Hugstetter Strasse 49
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, lomustine and procarbazine in primary central nervous system lymphoma (PCNSL), sponsored by Universitätsklinikum Freiburg - vertreten durch: Leitenden Ärztlichen Direktor Hugstetter Strasse 49. Started Oct 2010; status: completed.
02
Drugs
rituximabmethotrexatelomustineprocarbazine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on DRKS00000582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00000582.